BioSpace News Archive

Planet Fitness Raytown, Blue Springs and Independence are reopening their doors after upgrading the facilities and outfitting the clubs with new equipment.

Tomorrow at PAINWeek 2018, NeuroMetrix Inc. (Nasdaq: NURO), will unveil its latest breakthrough for the treatment of chronic pain

AdvanSource Biomaterials Corporation (OTCQB: ASNB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that the Company has entered into a multi-million dollar amendment of the current supply, royalty and license agreement with Access Scientific

QIAGEN N.V. announces that it will initiate the repurchase of a second tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018.

Imagine this: your child is playing a game of soccer or basketball. As they go to kick the ball or defend a shot, they accidentally collide with another player and they both end up on the ground, dazed and a little stunned

Rockwell Medical, Inc. today announced that Jim McCarthy, has been appointed Senior Vice President, Corporate and Business Development, effective September 4, 2018.

Sept. 4, 2018 21:00 UTC Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration VANCOUVER, British Columbia--( BUSINESS WIRE )-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collabora

GENFIT (Euronext: GNFT - ISIN: FR0004163111), is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases today announces the completion of enrolment in the Phase 2a trial evaluating elafibranor in PBC (Primary Biliary Cholangitis), a rare liver disease.

Dr. Jackie Fouse to step down as Executive Chair of Dermavant

Absorption Systems, a global leader in the science of translational medicine, announces that the Japanese Patent Office has issued a Decision to Grant a patent covering the In Vitro Dissolution Absorption System (IDAS2™), a groundbreaking, first-in-class technology.